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Background and rationale
Although pulmonary embolism (PE) is still considered to
be a ‘rare’ disease in the context of a population-based
incidence of ≈ 0.5 per 10 000 children per year [1], it is
nevertheless an important and increasingly recognized
condition in pediatrics, with substantial risks of mortality
and morbidity [2,3]. Unfortunately, these risks and
numerous other critical factors regarding pediatric PE
have historically been poorly characterized. In order to
advance our knowledge about pediatric PE, the Pediatric
and Neonatal Thrombosis and Hemostasis Subcommittee
of the ISTH established, in 2012, a pediatric PE Working
Group, whose specific tasks were to: systematically review
the existing literature on pediatric PE; identify instances
of heterogeneity in the definitions employed across stud-
ies; assess gaps in knowledge; and make recommendations
for standardization of definitions and key objectives for
future research.
The Working Group and collaborators have recently
published a systematic review of pediatric PE, including
studies from 1946 to 2013 [1], whose key findings are
summarized below:
1 Two distinct patterns of pediatric PE were recognized:
thromboembolic PE and in situ pulmonary artery
thrombosis (ISPAT), the definition of which is ‘in-situ
thrombosis of the pulmonary artery due to local
causes such as congenital heart disease, anomalies of
the pulmonary artery and lung transplantation’. Most
of the studies on risk factors, treatments and outcomes
included predominantly thromboembolic PE (where
specified).
2 Frequently reported risk factors among published
studies were immobilization (present in 38% of cases),
infection (31%), the presence of a central venous line
(CVL) (23%), surgery/trauma (22%), malignancy
(15%), hormonal contraception/pregnancy (15%), and
obesity (13%) [2–7].
3 Thrombophilia testing in children with PE was vari-
ably reported between studies, so it was difficult to
quantify increased susceptibility to PE or its adverse
outcomes in relation to laboratory markers.
4 The diagnosis of thromboembolic PE was frequently
delayed (probably because of a low index of suspicion
in pediatrics), with a mean lag time from symptom
onset to definitive diagnosis of ≈ 7 days (range 1–
11 days) [2,5–9].
5 Given the frequency of diagnosis at autopsy, the
reported incidence of pediatric PE is probably under-
estimated [8].
Correspondence: Tina Biss, Department of Haematology, The New-
castle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria
Infirmary, Newcastle upon Tyne, NE1 4LP, UK
Tel.: +44 191 282 4743
E-mail: tina.biss@nuth.nhs.uk
Received: 17 August 2017
Manuscript handled by: N. Mutch
Final decision: F. R. Rosendaal, 4 November 2017
© 2017 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 16: 405–408 DOI: 10.1111/jth.13902
6 Two pediatric-specific PE clinical prediction models
have been developed from retrospective cohort studies
[10,11], but neither has yet been validated in an inde-
pendent cohort or prospectively.
7 PE was diagnosed via computed tomographic pul-
monary angiography (CTPA) in three-quarters of
pediatric cases among reported series [1], but direct
comparisons of diagnostic performance among various
imaging modalities have not been published.
8 Anticoagulant therapy duration generally ranged from
3 months to 6 months [3].
9 The use of thrombolytic and thrombectomy approaches
(including surgical thrombectomy) was highly prevalent
among published studies, being reported in 29%, possi-
bly reflecting some reporting bias [12].
10 Data on long-term outcomes (in particular, functional
measures and quality of life [QoL]) and predictors of
outcome were sparse, and few prospective longitudinal
studies exist from which to generate hypotheses on
optimal management (to be subsequently tested in
interventional trials) [3,6].
Methods
The recommendations that are given here are based on
presentations at the Pediatric and Neonatal Thrombosis
and Hemostasis Subcommittee meetings during the 2014,
2015 and the 2016 meetings of the ISTH. In addition, the
Working Group further evaluated the available literature,
and agreed on consensus recommendations during face-
to-face meetings and teleconferences. The Working Group
was composed of M. Rajpurkar and N. A. Goldenberg
(co-leaders), T. T. Biss, A. K. C. Chan, C. H. van
Ommen, and S. Williams.
Major recommendations
• Education and awareness campaigns should focus on
facilitating the prompt investigation and diagnosis of
PE in children. This will require education to promote
the importance of recognizing respiratory symptoms
and signs, in combination with risk factor(s) for
venous thromboembolism (VTE), as potentially indi-
cating PE. Avoiding delay in diagnosis will probably
accelerate the initiation of treatment, potentially
improving outcomes. However, physicians must
remain mindful that judicious use of CTPA is impor-
tant, owing to the potential for unnecessary radiation
exposure during investigation for a low-incidence con-
dition.
• Institutions should develop protocols and strive to adopt
a standardized approach to the management of PE in
children. When they occur, variations from this
approach should be explicit and well documented. This
will increase the value of the data collected from
prospective and retrospective studies.
• Future cohort studies should be designed with the aim of
determining the factors that predict short-term and long-
term outcomes. These are likely to be prospective stud-
ies with subcategorizations such as age, the presence or
absence of provoking factors for thrombosis, and the
anatomic distribution of thrombus (Table 1). Measures
of clinical severity at presentation, e.g. respiratory and
hemodynamic status, echocardiogram or electrocardio-
gram evidence of right-heart strain, and elevation of
cardiac enzymes (Table 1), may allow risk stratifica-
tion, which, in turn, may predict the need for more
aggressive initial therapy, e.g. thrombolytic therapy, in
the case of high-risk presentations, or the potential for
outpatient management of low-risk presentations.
• The optimal intensity, duration and modality of
antithrombotic therapy, including mechanical and phar-
macologic thrombolysis and surgical thrombectomy, for
PE in children should be determined. Rather than
extrapolation from adult practice, this will require the
conduct of well-designed, clinical trials that are ade-
quately powered to determine differences in efficacy,
safety, and QoL. Measured outcomes should be both
clinical and radiologic, bearing in mind that the opti-
mal duration of therapy may be other than 3 months
Table 1 Potential prognostic factors to be addressed in future studies
of pediatric pulmonary embolism
Demographic features
Age
Gender
Provoking factors
CVL-related versus non-CVL-related
Short-term risk factor versus persistent risk factor
Presence of malignancy
Hormone-related versus non-hormone-related
Anatomic distribution of thrombus
Segmental versus subsegmental
Details of diagnosis
Time from onset of symptoms to diagnosis/treatment
Presenting features
Symptomatic* versus asymptomatic/subclinical
Hemodynamic compromise
ECG abnormalities indicating right-heart strain†
ECHO abnormalities indicating right-heart strain‡
Elevation of cardiac enzymes
Elevated D-dimer, inflammatory markers, other indices of
coagulation/fibrinolysis
Antithrombotic therapy
Nature of antithrombotic therapy, including thrombolysis
(systemic/catheter-directed) and mechanical thrombectomy
Intensity of anticoagulant therapy
Duration of anticoagulant therapy
Response to antithrombotic therapy
Degree of thrombus resolution
CVL, central venous line; ECG, electrocardiogram; ECHO, echocar-
diogram. *Dyspnea, hypoxemia, pleuritic chest pain, and unex-
plained tachycardia [2]. †ST/T segment changes, S1Q3T3, and
voltage criteria for right ventricular hypertrophy. ‡Tricuspid regurgi-
tation, septal flattening, and right ventricular dilation [3].
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[13]. Key areas of research will include the role of
thrombolysis and thrombectomy, and the duration of
therapy required.
• The optimal management of incidental/subclinical PE
should be evaluated. This will require the collection of
outcome data, with a comparison between treated and
untreated cases.
• Further data are required to determine the long-term out-
comes of pediatric PE. These include recurrence, exer-
cise capacity, and chronic thromboembolic pulmonary
hypertension (which should be clearly defined), and
also PE-specific QoL and the psychosocial impact of a
diagnosis of PE during childhood. Mortality should be
reported as both PE-related and all-cause mortality
(Table 2).
Other recommendations
• Clinical prediction models and D-dimer measurement
should undergo further evaluation as means of identifying
children with suspected PE who have a low pretest prob-
ability and therefore do not require imaging. These
should be specific to pediatrics, and should be prospec-
tively studied with both clinical and cost-economic
analyses. This may require subgroup analysis, e.g. inpa-
tient versus outpatient presentation, as the predictive
value may vary between subgroups.
• The most appropriate imaging modality should be deter-
mined in terms of sensitivity, specificity and acceptability
within a pediatric population. This should include the
evaluation of CTPA, pulmonary angiography, perfu-
sion scans, and magnetic resonance imaging-based
methods, taking into consideration radiation dose and
the ability to detect subsegmental PE.
• The role of thrombophilia as a risk factor for initial pre-
sentation with PE and recurrent thrombosis should be
investigated. This is most likely to be achieved by multi-
center prospective data collection by use of a standard
set of investigations for inherited and acquired throm-
bophilia [2,6].
The authors suggest that an important first step is to
collect high-quality, standardized, prospective data on the
presenting features and outcomes of pediatric PE from
multicenter, international studies.
Discussion
There is a significant burden associated with pediatric PE
in terms of mortality and of morbidity, which can be
both physical and psychosocial. Given the increasing
prevalence of pediatric VTE, it is likely that the incidence
of pediatric PE will also continue to rise [14].
The recent systematic review and meta-analysis of the
literature, coupled with these recommendations, have
identified a need for large-scale, prospective, multicenter
studies to evaluate aspects of pediatric PE [1]. Particular
emphasis should be placed on the design and execution of
high-quality cohort studies, as the challenges of conduct-
ing randomized clinical trials on rare pediatric disorders
are well known. Several key points and recommendations
from this work warrant emphasis and discussion. Stan-
dardization of definitions in relation to ISPAT, the sever-
ity of presentation, thrombophilia and outcomes is
required. The development of clinical scores and the iden-
tification of biomarkers that predict outcome are needed
in order to derive and validate prognostic models that
will inform risk stratification in future interventional tri-
als.
Existing clinical prediction rules that were developed in
adults lack sensitivity and specificity in a pediatric popu-
lation [10,15,16]. The negative predictive value of D-dimer
estimation requires further evaluation in children present-
ing with suspected PE [2,10,11]. A pediatric-specific clini-
cal prediction model developed by Hennelly et al.
requires the presence of one or more of hypoxia, tachy-
cardia and oral contraceptive pill use to trigger a high-
risk score [10]. A further model developed by Lee et al.
requires two or more of the following risk factors: immo-
bilization; hypercoagulable state; excess estrogen state;
indwelling CVL; and prior PE and/or deep vein thrombo-
sis [11]. These models have the potential to identify a
low-likelihood cohort of children with respect to PE who
may not require diagnostic imaging for PE, thereby
avoiding unnecessary exposure to radiation. However,
both were derived from single-center studies within ter-
tiary-care hospitals, and included a small number of con-
firmed cases of PE [10,11]. They would therefore require
evaluation in an independent cohort in addition to the
standardization of definitions such as ‘immobilization’.
Mortality rates are significant, but many deaths are
attributable to underlying disease states, and thrombosis-
related mortality occurs less often [1]. In addition, the
preponderance of retrospective studies carries a real
potential for reporting biases resulting in overestimation
of mortality. It is therefore important to assess long-term
outcomes (as shown in Table 2) in prospective
Table 2 Important outcome measures for future observational and
interventional studies of pediatric pulmonary embolism
Mortality
All-cause mortality
Thrombosis-related mortality
Bleed-related mortality
Morbidity
Thrombus recurrence
Physical morbidity
Exercise capacity
Pulmonary function
Presence of CTEPH
Hemorrhagic events
Psychosocial and behavioral morbidity
Quality of life
CTEPH, chronic thromboembolic pulmonary hypertension.
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cooperative studies. Although the psychosocial impact of
PE occurring in childhood has been little studied, previ-
ous evaluation of QoL tools for children and adolescents
receiving anticoagulant therapy suggest that there may be
psychological, behavioral and social problems associated
with this potentially life-threatening diagnosis, the burden
of anticoagulant monitoring, the need for lifestyle modifi-
cation, and the physical symptoms of PE [17,18].
The recommendations presented here serve as a call-to-
action for renewed focus and support regarding enhance-
ment of the quality and quantity of research in pediatric
PE, in order to advance our knowledge in the field and
ultimately improve outcomes for these children. Further
recommendations are likely to emerge from this future
work.
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